SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
NY AG Launches Probe Into Whether EpiPen Maker Scammed Schools
After price gouging scandal, Mylan now faces accusations of violating anti-trust laws
Sep 06, 2016
After stirring national outrage over its alleged price gouging of emergency allergy drug EpiPen, pharmaceutical giant Mylan is under fire once again for potentially violating anti-trust laws by inserting "potentially anticompetitive terms" into its EpiPen sales contracts to schools.
In a statement announcing the launch of a new investigation Tuesday, New York Attorney General Eric Schneiderman declared: "No child's life should be put at risk because a parent, school, or healthcare provider cannot afford a simple, life-saving device because of a drug-maker's anti-competitive practices."
Vowing to "bring the full resources of my office to this critical investigation," Schneiderman continued, "If Mylan engaged in anti-competitive business practices, or violated antitrust laws with the intent and effect of limiting lower cost competition, we will hold them accountable...Allergy sufferers have enough concerns to worry about--the availability of life-saving medical treatment should not be one of them."
A preliminary probe by the office of the New York AG reportedly found evidence suggesting that Mylan may have "locked schools into non-competitive contracts in order to purchase the EpiPens at an affordable price," according to Bloomberg, citing an undisclosed person familiar with the matter.
Echoing those concerns, Sens. Richard Blumenthal (D-Conn.) and Amy Klobuchar (D-Minn.) on Tuesday sent a letter to the Federal Trade Commission (FTC) calling on the agency "to issue Mylan an administrative subpoena to determine whether the company deliberately engaged in exclusionary practices to hinder its competitors and maintain its monopoly position in the market," The Hill reports.
The lawmakers cited a document that appeared to confirm allegations of the illegal contracts, which they said could be in violation of Section 5 of the Federal Trade Commission Act, which prohibits unfair methods of competition.
"The FTC must investigate whether Mylan has maintained its monopoly position through the use of these exclusive supply contracts, enabling the company to engage in price gouging for EpiPens by blocking rivals from becoming effective competitors," the letter stated.
The embattled drug-maker is already the subject of national scorn after it was revealed to have increased the price of the life-saving drug 400 percent since 2009, while at the same time rewarding company executives with exorbitant bonuses.
Attempts by the drugmaker to remedy the scandal, through the creation of discount programs and a generic alternative, were blasted last week by a group of 20 lawmakers, including progressive darlings Sens. Elizabeth Warren (D-Mass.) and Bernie Sanders (I-Vt.), as industry "shell games."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Lauren McCauley
Lauren McCauley is a former senior editor for Common Dreams covering national and international politics and progressive news. She is now the Editor of Maine Morning Star. Lauren also helped produce a number of documentary films, including the award-winning Soundtrack for a Revolution and The Hollywood Complex, as well as one currently in production about civil rights icon James Meredith. Her writing has been featured on Newsweek, BillMoyers.com, TruthDig, Truthout, In These Times, and Extra! the newsletter of Fairness and Accuracy in Reporting. She currently lives in Kennebunk, Maine with her husband, two children, a dog, and several chickens.
After stirring national outrage over its alleged price gouging of emergency allergy drug EpiPen, pharmaceutical giant Mylan is under fire once again for potentially violating anti-trust laws by inserting "potentially anticompetitive terms" into its EpiPen sales contracts to schools.
In a statement announcing the launch of a new investigation Tuesday, New York Attorney General Eric Schneiderman declared: "No child's life should be put at risk because a parent, school, or healthcare provider cannot afford a simple, life-saving device because of a drug-maker's anti-competitive practices."
Vowing to "bring the full resources of my office to this critical investigation," Schneiderman continued, "If Mylan engaged in anti-competitive business practices, or violated antitrust laws with the intent and effect of limiting lower cost competition, we will hold them accountable...Allergy sufferers have enough concerns to worry about--the availability of life-saving medical treatment should not be one of them."
A preliminary probe by the office of the New York AG reportedly found evidence suggesting that Mylan may have "locked schools into non-competitive contracts in order to purchase the EpiPens at an affordable price," according to Bloomberg, citing an undisclosed person familiar with the matter.
Echoing those concerns, Sens. Richard Blumenthal (D-Conn.) and Amy Klobuchar (D-Minn.) on Tuesday sent a letter to the Federal Trade Commission (FTC) calling on the agency "to issue Mylan an administrative subpoena to determine whether the company deliberately engaged in exclusionary practices to hinder its competitors and maintain its monopoly position in the market," The Hill reports.
The lawmakers cited a document that appeared to confirm allegations of the illegal contracts, which they said could be in violation of Section 5 of the Federal Trade Commission Act, which prohibits unfair methods of competition.
"The FTC must investigate whether Mylan has maintained its monopoly position through the use of these exclusive supply contracts, enabling the company to engage in price gouging for EpiPens by blocking rivals from becoming effective competitors," the letter stated.
The embattled drug-maker is already the subject of national scorn after it was revealed to have increased the price of the life-saving drug 400 percent since 2009, while at the same time rewarding company executives with exorbitant bonuses.
Attempts by the drugmaker to remedy the scandal, through the creation of discount programs and a generic alternative, were blasted last week by a group of 20 lawmakers, including progressive darlings Sens. Elizabeth Warren (D-Mass.) and Bernie Sanders (I-Vt.), as industry "shell games."
Lauren McCauley
Lauren McCauley is a former senior editor for Common Dreams covering national and international politics and progressive news. She is now the Editor of Maine Morning Star. Lauren also helped produce a number of documentary films, including the award-winning Soundtrack for a Revolution and The Hollywood Complex, as well as one currently in production about civil rights icon James Meredith. Her writing has been featured on Newsweek, BillMoyers.com, TruthDig, Truthout, In These Times, and Extra! the newsletter of Fairness and Accuracy in Reporting. She currently lives in Kennebunk, Maine with her husband, two children, a dog, and several chickens.
After stirring national outrage over its alleged price gouging of emergency allergy drug EpiPen, pharmaceutical giant Mylan is under fire once again for potentially violating anti-trust laws by inserting "potentially anticompetitive terms" into its EpiPen sales contracts to schools.
In a statement announcing the launch of a new investigation Tuesday, New York Attorney General Eric Schneiderman declared: "No child's life should be put at risk because a parent, school, or healthcare provider cannot afford a simple, life-saving device because of a drug-maker's anti-competitive practices."
Vowing to "bring the full resources of my office to this critical investigation," Schneiderman continued, "If Mylan engaged in anti-competitive business practices, or violated antitrust laws with the intent and effect of limiting lower cost competition, we will hold them accountable...Allergy sufferers have enough concerns to worry about--the availability of life-saving medical treatment should not be one of them."
A preliminary probe by the office of the New York AG reportedly found evidence suggesting that Mylan may have "locked schools into non-competitive contracts in order to purchase the EpiPens at an affordable price," according to Bloomberg, citing an undisclosed person familiar with the matter.
Echoing those concerns, Sens. Richard Blumenthal (D-Conn.) and Amy Klobuchar (D-Minn.) on Tuesday sent a letter to the Federal Trade Commission (FTC) calling on the agency "to issue Mylan an administrative subpoena to determine whether the company deliberately engaged in exclusionary practices to hinder its competitors and maintain its monopoly position in the market," The Hill reports.
The lawmakers cited a document that appeared to confirm allegations of the illegal contracts, which they said could be in violation of Section 5 of the Federal Trade Commission Act, which prohibits unfair methods of competition.
"The FTC must investigate whether Mylan has maintained its monopoly position through the use of these exclusive supply contracts, enabling the company to engage in price gouging for EpiPens by blocking rivals from becoming effective competitors," the letter stated.
The embattled drug-maker is already the subject of national scorn after it was revealed to have increased the price of the life-saving drug 400 percent since 2009, while at the same time rewarding company executives with exorbitant bonuses.
Attempts by the drugmaker to remedy the scandal, through the creation of discount programs and a generic alternative, were blasted last week by a group of 20 lawmakers, including progressive darlings Sens. Elizabeth Warren (D-Mass.) and Bernie Sanders (I-Vt.), as industry "shell games."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.